These antibodies have been called “dominant” antagonistic antibodies due to their ability to diminish human ovarian cancer cells in the ascites and cutaneous T cell lymphoma, even under TNF induction. This evidence concerns the gene TNF and primary cutaneous T-cell non-Hodgkin lymphoma.